Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida
SAN FRANCISCO, CA / ACCESSWIRE / October 24, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that its president and CEO, Lisa Conte, will be hosting investor meetings at the 4th Annual Dawson James Small Cap Growth Conference on Tuesday, October 30, 2018 in Jupiter, Florida at the Wyndham Grand Jupiter at Harbourside Place.
Ms. Conte will be available for one-on-one meetings with new and existing investors and analysts at the conference. Those interested in scheduling a one-on-one meeting with Ms. Conte should contact Marek Ciszewski, J.D. at marek@liolios.com.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
